Study Short Title	Full Title	Name of PI	Dates	Status
BHIVA COVID-19 Registry	British HIV Association (BHIVA) COVID-19 Registry	Caroline Sabin	October 2020 - ongoing	Current
Association of HIV with outcomes of COVID-19 hospitalization outcomes	Outcomes of COVID-19-related hospitalization among people with HIV in the ISARIC World Health Organization (WHO) Clinical Characterization Protocol (UK)	Caroline Sabin	May 2020 - ongoing	Current
UK community survey of COVID/HIV	Community Survey of the experiences of COVID-19 on people living with HIV in the UK	Caroline Sabin	June 2020 - ongoing	Current
SEPAC	Screening and early detection to prevent anal cancer; development of a biomarker screening tool	Richard Gilson	April 2019 to March 2022	Current
ASSIST	Assessing the impact of introducing online postal self-sampling for sexually transmitted infections into sexual health provision within the UK on health inequalities, access to care and clinical outcomes	Fiona Burns and Jo Gibbs	1st January 2021 to 31st March 2024	Current
SIREN (Sarscov2 Immunity & REinfection EvaluatioN)	Impact of detectable anti-SARS-COV2 on the subsequent incidence of COVID-19 in healthcare workers	Alejandro Arenas-Pinto	September 2020 to September 2022	Current
Analysing immune responses to vaccination	Analysing humoral and cellular immune responses to vaccination during chronic infection	Dimitra Peppa, Richard Gilson, Laura Waters	October 2020 to October 2025	Current
ICOS	International SARS-CoV-2 Infection Observational Study	Richard Gilson	27th May 2020 - (ongoing)	Recruiting
Jenner II	Temporal analysis of host immune responses and mechanisms impairing control of viral replication of during the course of HIV-1 infection	Dimitra Peppa		Recruiting
Chips+	CHIPS+: Optimising the health of young people with HIV in their transition from paediatric to adult care	Alistair Teague		Recruiting
WISARD	AN OPEN-LABEL, MULTI-CENTRE, RANDOMISED, SWITCH STUDY TO EVALUATE THE VIROLOGICAL EFFICACY OVER 96 WEEKS OF 2-DRUG THERAPY WITH DTG/RPV FDC IN ANTIRETROVIRAL TREATMENTEXPERIENCED HIV-1 INFECTED SUBJECTS VIROLOGICALLY SUPPRESSED WITH NNRTIS RESISTANCE MUTATION K103N.	Laura Waters		Recruiting
LAPTOP	An Open-Label, Multi-Centre, Randomised Study to Investigate Integrase Inhibitor Versus Boosted Protease Inhibitor Antiretroviral Therapy for Patients with Advanced HIV Disease – The Late Presenter Treatment Optimisation Study (LAPTOP)	Robert Miller		Recruiting
PIBIK	A Phase IV Randomised, Open-Label Pilot Study to Evaluate Switching from Protease-Inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide Single Tablet Regimen in Integrase Inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations	Laura Waters		Recruiting
DOLOMITE	DOLOMITE NEAT ID Network Study: A multi- site observational study to define the safety and effectiveness of Dolutegravir use in HIV positive pregnant women	Sherie Roedling		Recruiting
INTUIT	Interaction Design for Trusted Sharing of Personal Health Data to Live Well with HIV	Jo Gibbs		Closed for recruitment
HIV Bioresource		Fiona Burns		Paused
Elite Controllers	HIV elite controllers: Comprehensive assessment of host factors associated with HIV-1 elite control	Ravi Gupta		Paused
SALSA	A Phase III, randomized, multicenter, open-label, non-inferiority study evaluating the efficacy, safety and tolerability of switching to dolutegravir/lamivudine fixed dose combination in HIV-1 infected adults who are virologically suppressed	Sarah Pett		In follow up
River	RIVER - Research in Viral Eradication of HIV Reservoirs - a functional cure study	Sarah Pett		In follow up
GS-1489	GS-US-380-1489: A phase 3, randomised, Double Blind Study to Evaluate the Safety and Efficacy of GS9883/FTC/TAF vs. Triumeq in HIV-1 Infected, Antiretroviral Treatment Naïve Adults	Laura Waters		In follow up
GS-1490	GS-US-380-1490: A Phase 3, Randomised, Double Blind Study of the Safety and Efficacy of a Fixed Dose combination of GS9883/FTC/TAF vs. DOL/FTC/TAF in HIV-1 infected, Antiretroviral Treatment- Naïve Adults	Laura Waters		In follow up
Merck 021	MK-1439A-021: Double-Blind, Randomised Trial of Safety and Efficacy of FDC of TDF/3TC/doravirine (MK1439A) Once Daily vs Atripla® in Treatment Naïve HIV-positives	Ian Williams		In follow up
Merck 024	MK-1439A-024: randomised study evaluating immediate vs deferred switch to  FDC of TDF/3TC/doravirine in patients stable and suppressed on a PI/r+2NRTI	Ian Williams		In follow up
Merck 018	A Phase 3 Multicenter, Double-Blind, Randomized, Active Comparator-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Doravirine (MK-1439) 100 mg Once Daily Versus Darunavir 800 mg Once Daily plus Ritonavir 100 mg Once Daily, Each in Combination with TRUVADA™ or EPZICOM™/KIVEXA™, in Treatment-Naïve HIV-1Infected Subjects.	Ian Williams		In follow up
POPPY	The POPPY (Pharmacokinetic and clinical Observations in PeoPle over fiftY) Study	Caroline Sabin		In follow up
POPPY Sleep	POPPY Sleep Substudy: study looking at the effects of being HIV positive and being on antiretroviral medication may have on sleeping and sleep pattern	Caroline Sabin		In follow up
START	Strategic Timing of AntiRetroviral Treatment (START): Randomized study to determine whether immediate initiation of antiretroviral treatment (ART) is superior to deferral of ART until the CD4+ declines below 350 cells/mm3	Ian Williams		In follow up
Eurosida 9	EuroSIDA Cohort 9: Observational cohort study collecting clinical and demographic data for HIV-positive adults.	Simon Edwards		In follow up
Eurosida 10	EuroSIDA Cohort X: Observational cohort study collecting clinical and demographic data for coinfected HIV/HCV positive adults.	Simon Edwards		In follow up
FLAIR	FLAIR: A Phase III, Randomized, Multicenter, Parallel-group, Open-Label Study Evaluating the Efficacy and Safety of Long-Acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch from an Integrase Inhibitor Single Tablet Regimen in HIV-1 Infected ART-Naive Adult Participants	Sarah Pett	Nov 2016 - current	In follow up
DISCOVER	GS-US-412-2055: A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are At Risk of HIV-1 Infection	Richard Gilson		In follow up
TANGO	A Phase III, randomized, multicenter, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus lamivudine in HIV-1-infected adults who are virologically supressed	Sarah Pett	Apr 2018 - current	In follow up
SAFETXT	Safetxt: randomised controlled trial of safer sex intervention delivered through mobile phone messaging	John Saunders		In follow up
MAVMET	MAVMET: a multicentre, 48 week randomised controlled factorial trial of adding Maraviroc and/or Metformin for hepatic steatosis in HIV-1-infected adults on combination antiretroviral therapy	Sarah Pett		In follow up
PETRAM	Understanding changes in treatment-related regional bone turnover using 18F-fluoride-PET/CT in HIV-1-infected men: PETRAM study	Sarah Pett		In follow up
SAFER (UCLH)		Nina Vora		In follow up
PrEP IMPACT Trial	PrEP IMPACT Trial: A pragmatic health technology assessment of PrEP and implementation.	Richard Gilson		Completed
POPPY LIVER	Hepatic steatosis in people living with HIV older than 50 years of age: The POPPY Hepatic Steatosis Sub-Study	Alejandro Arenas-Pinto		Completed
ECLEAR	Early administration of anti-latency reversing therapy and broadly neutralizing antibodies to limit the establishment of the HIV-1 reservoir during initiation of antiretroviral treatment - a randomized controlled trial (eCLEAR)	Erica Pool		Completed
BESTT	BESTT WOMEN's STUDY: Bone Evaluation in HIV positive women who switch from Truvada/NNRTI to Triumeq	Laura Waters	May 2016 – Apr2020	Completed
VITA	VITA: A randomised controlled trial to assess the clinical and cost effectiveness of topical lactic acid gel for treating second and subsequent episodes of bacterial vaginosis	Richard Gilson	Nov 2017 – Jun 2019	Completed
BRIDGE-IT	A randomised controlled trial to determine the effectiveness of bridging from emergency to regular contraception: The Bridge –it study	Richard Gilson		Completed
PRIME FSH	PRIME Ovarian Biomarker Study: Biomarkers of ovarian ageing in postmenopausal women living with HIV - a prevalence study	Rob Miller/Shema Tariq		Completed
PROUD	PRe-exposure Option for reducing HIV in the UK: an open-label randomisation to immediate or Deferred daily Truvada for HIV negative gay men	Richard Gilson		Completed
H-ART 2 HEART	Deep Cardiovascular Phenotyping of People with HIV on Anti-Retroviral Therapy at risk of Heart Disease	Richard Gilson		Completed
GENAFRICA	Genetic markers of kidney disease progression in people of African heritage in the UK CHIC cohort	Sarah Pett		Completed
CIPHER	CIPHER - study of cognitive function in HIV+ people.	Lewis Haddow		Completed
AMBER	AMBER - randomised, double-blind study to evaluate efficacy and safety of DRV/cobicistat/FTC/TAF vs. DRV/cobicistat fixed dose combination plus Truvada®	Laura Waters		Completed
EMERALD	EMERALD: randomized, active-controlled, open-label study to evaluate the efficacy and safety of switching to a D/C/F/TAF once-daily single-tablet regimen versus continuing the current regimen consisting of a boosted protease inhibitor (bPI) combined with FTC/TDF	Laura Waters		Completed
FLU STUDY	Influenza acquisition in Health Care Workers who work on a dedicated influenza cohort ward	Richard Gilson		Completed
STOP HCV-1	STOP HCV-1: Stratified Treatment OPtimisation for HCV-1: An open-label randomised controlled trial (RCT) testing biomarker-stratified short-course first-line and re-treatment direct-acting antiviral (DAA) oral treatment regimens to cure mild chronic Hepatitis C (HCV) disease.	Richard Gilson		Completed
PARTNER	PARTNER 2.0: A study in HIV sero-different partnerships to estimate the rate of transmission of HIV and to investigate factors associated with condom use	Richard Gilson		Completed
POSITIVE VOICES	Positive Voices: The national survey of people living with HIV	Richard Gilson		Completed
START	Strategic Timing of AntiRetroviral Treatment (START): Randomized study to determine whether immediate initiation of antiretroviral treatment (ART) is superior to deferral of ART until the CD4+ declines below 350 cells/mm3	Ian Williams		Completed
HIPVAC	HIPvac: Randomised controlled trial of Imiquimod cream vs. podophyllotoxin in combination with quadrivalent HPV or control vaccination in the treatment and prevention of recurrence of anogenital warts.	Richard Gilson	Feb 2014 - current	Completed
SYPHILIS TRANSCRIPTOMICS	Syphilis Transcriptomics: Proof of concept study that aims to utilise next generation sequencing and transcriptomic approaches to understand infection with Treponema pallidum	Patrick French	Oct 2017 - current	Completed
HPV SAMPLING	HPV Sampling Study: A study to evaluate the performance of human papillomavirus (HPV) DNA detection in residual specimens taken for Chlamydia trachomatis/Neisseria gonorrhoea nucleic acid amplification testing in men who have sex with men (MSM)	Diarmuid Nugent	Jan 2018 - current	Completed
PRIME	PRIME: Quantitative and qualitative study that will exploring the impact of the menopause on HIV-positive women's health and wellbeing	Shema Tariq	Jan 2016 – Oct 2017	Completed
UK HDRD	UK HIV Drug Resistance Database	David Dunn	2001 – current	Completed
GS-1823	GS-US-292/1823: A Phase 3b, Randomised, Open-Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of ABC/3TC plus a Third Antiretroviral Agent to the E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adult Subjects	Laura Waters	Sep 2016 – May 2018	Completed
GS-1826	GS-US-292-1826: A Phase 3b, Randomised, Open-Label Study to Evaluate Switching from a TDF Containing Regimen to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Subjects Aged ≥ 60 Years	Laura Waters	Aug 2016 – Mar 2018	Completed
POPPY NEW WAVE		Ian Williams		Upcoming
EAGLE		Richard Gilson		Upcoming
RIO		Sarah Pett		Upcoming
DEVA		Richard Gilson		Upcoming
DOR-DOL		Laura Waters		Upcoming
PREP DLM		John Saunders		Upcoming
SKIN CANCER QUESTIONNAIRE		Alejandro Arenas-Pinto		Upcoming
WEIGHT GAIN STUDY		Alejandro Arenas-Pinto		Upcoming
ANTIMICROBIAL PROPHYLAXIS SURVEY (POPS)		John Saunders		Upcoming